[ET Net News Agency, 27 July 2020] CSPC Pharmaceutical Group Limited (01093) said the
"Duloxetine Hydrochloride Enteric Capsules (20mg, 30mg, 60mg)" developed by CSPC Ouyi
Pharmaceutical Co., Ltd., a subsidiary of the company, has obtained drug registration
approval granted by the National Medical Products Administration of the People's Republic
of China, being the second generic drug of this type passing the consistency of quality
and efficacy evaluation in China.
Duloxetine hydrochloride is a nervous system drug indicated for the treatment of major
depressive disorder, generalized anxiety disorder and chronic musculoskeletal pain. (RC)